Skip to content
mielomamultiplo.com · Multiple Myeloma
Emergency 112  · SNS 24 808 24 24 24
The Multiple Myeloma symbol — find out what it means

Multiple Myeloma There is hope. There is a way forward.

information · support · hope

It is always better to be an informed patient.

News, testimonies, a space to share ideas and links that help patients and carers understand the disease better and know where to find help.

Automatic translation by MielomaAI. The original text is in Portuguese. Some parts may still appear in Portuguese while they are being translated. Português
Films: types of myeloma and how each treatment is given

Bispecifics before CAR-T: Why order matters

The antibodies Specific biomarkersAntibodies with two “arms”: one grabs the T lymphocyte and the other the myeloma cell, joining them so that the lymphocyte destroys. Examples: teclistamab, elranatamab, talquetamab. e o CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. These are two very powerful weapons against myeloma. They target the same thing, and one attacking it can weaken the other.

Important information

The same target: the BCMA

O CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. Carvykti and the Specific biomarkersAntibodies with two “arms”: one grabs the T lymphocyte and the other the myeloma cell, joining them so that the lymphocyte destroys. Examples: teclistamab, elranatamab, talquetamab. Teclistamab (Tecvayli) and elranatamab (Elrexfio) recognize the same protein on the surface of the myeloma cell: the BCMAThe protein found on the surface of myeloma cells (B cell maturation antigen). It is the target of CAR-T Carvykti and the bispecific teclistamab and elranatamab..

Common target

How does BIESPECIFIC work?

The bispecific approach simultaneously engages a patient’s T lymphocyte and myeloma cell, causing the lymphocyte to attack it. This occurs over months, weekly or every two weeks.

Continuous treatment

Reason 1: The target can disappear

After a long time being attacked by… BCMAThe protein found on the surface of myeloma cells (B cell maturation antigen). It is the target of CAR-T Carvykti and the bispecific teclistamab and elranatamab., some myeloma cells stop showing it or changing it. Without a target, the CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. The anti-BCMA no longer recognizes it.

Loss of target

Reason 2: T lymphocytes get tired

The specific factor puts the… T lymphocytesWhite blood cells that attack cancerous cells. These are the ones that myeloma patients and specialists put to work attacking the myeloma, and these are used to manufacture CAR-T. working non-stop and they become “exhausted”. Now, let’s… CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. It is manufactured from the patient’s own T lymphocytes: if they are tired, the CAR-T cells come out weaker.

Fatigued lymphocytes

What do the numbers show?

In a study in the US with CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. anti-BCMAThe protein found on the surface of myeloma cells (B cell maturation antigen). It is the target of CAR-T Carvykti and the bispecific teclistamab and elranatamab.88% of patients responded to the treatment without prior BCMA anti-body therapy and 74% of those who had previously received it. The time without disease progression decreased from approximately 9 to approximately 3 months.

Worse results after

Time is of the essence.

The closer you are to treatment…BCMAThe protein found on the surface of myeloma cells (B cell maturation antigen). It is the target of CAR-T Carvykti and the bispecific teclistamab and elranatamab.It's worse: whoever received it CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. Less than 6 months later, the responses decreased even further.

Less than 6 months: worse

It's not forbidden, but…

There's no rule that prevents it: some patients do. CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. after a specific and respond. But the probability of resulting is lower and the response tends to last less.

Possible, with fewer options

Therefore: CAR-T first

These recommendations…IMWGInternational Myeloma Working Group: an international group of experts who publish recommendations on the diagnosis and treatment of myeloma.They say that those who are being considered CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. anti-BCMAThe protein found on the surface of myeloma cells (B cell maturation antigen). It is the target of CAR-T Carvykti and the bispecific teclistamab and elranatamab. Should be done before other BCMA-directed treatments. If needed to control the disease while waiting, a treatment targeting another aim is preferred.

The recommended order

Another target: GPRC5D

The talquetamab (Talvey) is a bispecific that targets another target, the This is a gene associated with multiple myeloma.Another protein on myeloma cells, different from BCMA. It is the target of the bispecific talquetamab (Talvey).Don’t “waste” it. BCMAThe protein found on the surface of myeloma cells (B cell maturation antigen). It is the target of CAR-T Carvykti and the bispecific teclistamab and elranatamab.So, when a specific is needed before... CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion.It is preferred by specialists.

Different target

In Portugal

Carvykti, Tecvayli and Elrexfio have been approved for the same stage: after 3 or more treatments. The order is decided by the team. Talk about CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. Speak to your hematologist early, before starting a specific biotherapy.

The same phase

Questions to ask your team

I am a patient. CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion.? If you do a specific biopsy first, will I have fewer options? There is a Bridging treatmentTreatment is given while waiting for the CAR-T (which takes weeks to be manufactured) to keep the disease under control. What's your target? What's the nearest CAR-T center to me?

Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Important information, simplified for patients. The decision about the order of treatments is always made by the hematology team, on a case-by-case basis. Source: Ferreri et al., Blood Cancer Journal 2023 (CAR-T depois de terapêutica anti-BCMA); Targeted Oncology 2025 ↗ · This does not replace the explanation from your medical team.

Types of Multiple Myeloma

It arises from the myeloma. plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody., as células da bone marrowThe soft tissue inside the bones where blood cells are made: red blood cells, white blood cells, platelets, and plasma cells. It is examined with a bone marrow tap (bone marrow scan) or biopsy. What antibodies do. Not all multiple myeloma are the same: they change phase, the protein they produce and the risk.

Before myeloma: MGUS

There is plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. modified and a little abnormal protein in the blood (a) protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working.), but without symptoms or damage. It's not cancer and it's not treated: it's monitored with tests.

Progresses slowly: about 1% per year

Smouldering myeloma

More protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working.Or 10% or more plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. in the bone marrow, but without damage to the organs. Most cases are monitored; in latentSmoldering myeloma: protein M of 3 g/dL or higher, or 10% to 60% plasma cells in the bone marrow, but without organ damage. Approximately 10% per year evolve to active myeloma in the first 5 years. High risk may already be treatable.

Close monitoring

Active myeloma

When myeloma has already caused damage – high calcium, kidneys affected, AnemiaLack of red blood cells or hemoglobin in the blood. Causes fatigue, paleness, and shortness of breath. or bone injuries (the signsCRABThe English acronym for the 4 typical damages of myeloma: C for high calcium in the blood, R for kidneys (kidney failure), A for anemia, and B for bone, i.e., lesions in the bones. Just one of these is enough to speak of active myeloma.) — or when tests show it’s going to cause it soon. Then treatment is needed.

It needs to be treated.

The protein type

Each antibody has 2 heavy chainsThe larger parts of an antibody. There are 5 types – G, A, D, E and M – and they are what give the immunoglobulin its name: IgG, IgA, IgD, IgE or IgM. e 2 fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone.. Multiple myeloma is named after the heavy chain (G, A, D, E or M) and the light chainkappaOne of the two light chain types. Approximately 2 in every 3 multiple myeloma cases are kappa. or That's a good question.One of the two light chain types. Approximately 1 in every 3 multiple myeloma cases is lambda; it is also the most common type in AL amyloidosis.:) for example, “IgG kappa”.

Discovered with immunofixation

IgG and IgA

IgG is the most common: more than half of patients. IgA follows, and more often forms tumors outside of the bones. The treatment is generally the same.

The most common

Light Chain Myeloma

Approximately 1 in every 5 patients only produces fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. It (the protein) Bence JonesOld term for light chains found in urine. It comes from the English doctor who described them in the 19th century.). They are small and can block the kidneys, which need extra attention. Followed by with... free catenaryLoose pieces of antibody floating in the blood. The two types (kappa and lambda) are measured, as well as the ratio between them; a very high alteration indicates a clone of plasma cells. in the blood.

Around 20% of patients

Rare conditions

IgD, IgE and IgM are rare. In smoldering myeloma (1-2% of patients), there is almost no protein detected in the blood tests: follow-up with bone marrow examination and imaging tests, such as PETPositron emission tomography (PET) scan that shows the areas of the body with very active cells. Helps to see lesions in the bones and disease outside the bone marrow..

Rare

Solitary plasmacytoma

A single tumor plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody.It can be in a bone, or outside of one, without myeloma in the rest of the bone marrow. It is often treated with radiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. and then you are monitored, as it can progress.

Radiotherapy and monitoring

The most dangerous: genetics

Some changes in the chromosomes of myeloma cells make the disease more aggressive: loss of 17pA fragment of chromosome 17 where the TP53 gene is located, which controls cell growth. If it is lost (17p deletion), the myeloma tends to be more aggressive. or mutation TP53Gene that acts as a brake on cells. When it is altered (mutated or lost), the myeloma responds worse to some treatments., e t(4;14)Translocation: exchange of pieces between chromosomes 4 and 14. It doesn't count as high risk on its own; it does count when it's associated with gains in 1q or losses in 1p.t(14;16) or t(14;20) when joining to gain 1qLong arm of chromosome 1. Having extra copies (a gain of 1q) is common and makes the disease more difficult to control, especially when combined with other changes. or a loss of 1 point. Two or more: even greater risk.

High risk

The most dangerous: outside the bone marrow

A Multiple myelomaRare and very aggressive condition: there are 5% or more plasma cells circulating in the blood. It can occur at the onset (primary) or as a relapse of myeloma (secondary). (5% or more) plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. (circulating in the blood) and the extramedullary diseaseMultiple myeloma with extramedullary deposits in organs or soft tissues, away from the bones (skin, liver, lymph nodes, nervous system). This indicates a more aggressive disease. Extramedullary disease is the most aggressive form.

Very high risk

The most common treatment at the beginning

Today, a combination of 4 medications is often used: one anti-CD38Antibodies (daratumumab, isatuximab) that bind to the CD38 protein, which is very prevalent in myeloma cells, and mark them for destruction by the immune system. (daratumumab), a proteasome inhibitorMedications (bortezomib, carfilzomib, ixazomib) that block the protein “breaker” in the cell. The myeloma cells, which produce a lot of protein, accumulate waste and die. (bortezomib), a immunomodulatorTablets (lenalidomide, pomalidomide, talidomide) that inhibit myeloma and help the body’s defenses attack it. lenalidomide and a corticosteroidCorticosteroid medications, such as dexamethasone. At high doses, they kill myeloma cells and enhance the effect of other medications. (dexamethasone)

Introduction: several months

After the induction

Who can, does. allogeneic transplantStem cells are collected from the patient's own body, followed by intensive chemotherapy (melfalan) and then the cells are returned to the bone marrow to recover.And it involves using your own stem cells. Following this... MaintenanceMilder and longer treatment after induction and transplant, to keep the myeloma under control for a longer period. Often it is lenalidomide in tablet form.Generally, with lenalidomide, to keep the disease under control.

Transplant and maintenance

If the disease returns

There are other weapons: new combinations, antibodies. Specific biomarkersAntibodies with two “arms”: one grabs the T lymphocyte and the other the myeloma cell, joining them so that the lymphocyte destroys. Examples: teclistamab, elranatamab, talquetamab. e CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion.In high-risk myeloma, doctors often treat more intensively and may propose clinical trialsStudies comparing a new treatment with the best existing treatment may provide access to medications before approval. Participation is voluntary..

Relapse

Taking care of the rest of your body

In all types: medications to strengthen bones, vaccines and prevention of infections, and attention to the kidneys are part of the treatment.

Always

All types, one by one

Under the film is the complete list: each type, what it is, how it progresses or is treated, and the risk, including related diseases, such as Amyloidosis ALDisease in which the light chains misfold and deposit themselves in the organs (heart, kidneys, nerves), damaging them. It can exist on its own or with multiple myeloma. e a POEMSRare syndrome linked to a plasma cell clone (almost always lambda): Polyneuropathy, Organomegaly, Endocrinopathy, M Protein and Skin Changes..

Movie listings below

Ask what your symptoms are.

Each myeloma is different. Ask your team: what is my type, what stage am I in, and what is my risk? There is hope, there is a path.

Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Simplified explanation for patients and families. The type, stage and risk for each person can only be determined by the hematology team. Source: International Myeloma Foundation — Types of Myeloma ↗ · This does not replace the explanation from your medical team.

All types, one by one

Click on a type to open. Hover over (or tap) the underlined words to see what they mean.

Before myeloma

MGUS is not IgM.
What is it?
Protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. Low levels of IgG or IgA, less than 10%. plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. in the bone, without damage to the body. It is the most common form MGUSMonoclonal gamopathy of undetermined significance. There is protein M (less than 3 g/dL) and less than 10% plasma cells in the bone marrow, without organ damage. It affects approximately 3 in 100 people over 50 years old, and most will never develop myeloma..
How to follow up or manage
This isn't a cure. Tests are usually done 6 months after diagnosis and then once a year, or as needed based on risk.
Risk
Low: approximately 1% per year progresses to myeloma.
MGUS IgM
What is it?
Protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. Of the IgM type, without causing any damage to the body.
How to follow up or manage
Monitoring with analyses.
Risk
It can mainly progress to multiple myeloma. WaldenströmWaldenström macroglobulinemia: a lymphoma that produces IgM protein. It is not multiple myeloma and is treated differently. or another lymphoma, rarely for myeloma.
Light Chain MGUS
What is it?
Just fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. changes in the blood, without protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. complete and without harm.
How to follow up or manage
Monitoring with tests, including kidney assessments.
Risk
Low; can progress to myeloma fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. or Amyloidosis ALDisease in which the light chains misfold and deposit themselves in the organs (heart, kidneys, nerves), damaging them. It can exist on its own or with multiple myeloma..
Smouldering myeloma
What is it?
Protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. 3 g/dL or more, or 10% to 60% plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. in the bone marrow, but without signs CRABThe English acronym for the 4 typical damages of myeloma: C for high calcium in the blood, R for kidneys (kidney failure), A for anemia, and B for bone, i.e., lesions in the bones. Just one of these is enough to speak of active myeloma..
How to follow up or manage
Close monitoring (every 3 or 6 months), with imaging tests. No latentSmoldering myeloma: protein M of 3 g/dL or higher, or 10% to 60% plasma cells in the bone marrow, but without organ damage. Approximately 10% per year evolve to active myeloma in the first 5 years. high risk may involve daratumumab or entering a clinical trial.
Risk
Approximately 10% per year for the first 5 years. High risk when there are 2 or 3 of these: more than 20% plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody., protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. above 2 g/dL, reason for fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. Over 20.

Active myeloma

Multiple myeloma active
What is it?
Plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. multiple myeloma in the bone marrow with damage CRABThe English acronym for the 4 typical damages of myeloma: C for high calcium in the blood, R for kidneys (kidney failure), A for anemia, and B for bone, i.e., lesions in the bones. Just one of these is enough to speak of active myeloma. (calcium, kidneys, ) AnemiaLack of red blood cells or hemoglobin in the blood. Causes fatigue, paleness, and shortness of breath.... (bones) or with signs that they are about to cause them: 60% or more plasma cells, reason of fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. Of 100 or more, or more than one bone lesion seen on the scan.
How to follow up or manage
Treatment of inductionThe first phase of treatment aims to reduce the myeloma levels as much as possible. It usually lasts for several months. (often 4 medications) allogeneic transplantStem cells are collected from the patient's own body, followed by intensive chemotherapy (melfalan) and then the cells are returned to the bone marrow to recover. in whom it may concern MaintenanceMilder and longer treatment after induction and transplant, to keep the myeloma under control for a longer period. Often it is lenalidomide in tablet form..
Risk
It depends on the stage (R-ISS) and genetics.

Types by protein (immunofixation)

IgG (kappa or lambda)
What is it?
The most common type: more than half of patients.
How to follow up or manage
Typical treatment for myeloma. Followed by… protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. in the blood.
Risk
Just like overall; the risk depends mainly on genetics and stage.
IgA (kappa or lambda)
What is it?
The second most common, about 1 in every 5 patients.
How to follow up or manage
Standard treatment. Sometimes it protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. It is measured worse and IgA dosage is also used.
Risk
More frequently, tumors outside of the bones.
Light chains (Bence Jones), kappa or lambda
What is it?
Just produces fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone., without the heavy chain. Around 15% to 20% of patients.
How to follow up or manage
Standard treatment, with particular attention to the kidneys (hydration, avoiding anti-inflammatory drugs). Followed by… free catenaryLoose pieces of antibody floating in the blood. The two types (kappa and lambda) are measured, as well as the ratio between them; a very high alteration indicates a clone of plasma cells. in the blood.
Risk
Increased risk of kidney injury.
IgD
What is it?
Rare: about 1 to 2% of patients. Almost always That's a good question.One of the two light chain types. Approximately 1 in every 3 multiple myeloma cases is lambda; it is also the most common type in AL amyloidosis. and in younger people too.
How to follow up or manage
Standard treatment; often proposes transplant.
Risk
Further kidney damage and disease outside the bone marrow; may be associated with Multiple myelomaRare and very aggressive condition: there are 5% or more plasma cells circulating in the blood. It can occur at the onset (primary) or as a relapse of myeloma (secondary)..
IgE
What is it?
Very rare: less than 1 in 1000 patients.
How to follow up or manage
Typical treatment.
Risk
It tends to be more aggressive and spread to the bloodstream.
IgM
What is it?
Very rare. It is necessary to distinguish from macroglobulinemia. WaldenströmWaldenström macroglobulinemia: a lymphoma that produces IgM protein. It is not multiple myeloma and is treated differently.Also produces IgM but is a lymphoma.
How to follow up or manage
Treatment of myeloma, after diagnosis has been confirmed.
Risk
More difficult to diagnose; tends to be more aggressive.
Biclonal
What is it?
Rare (1-2%) : there are two different M proteins present at the same time.
How to follow up or manage
Typical treatment; followed by the two proteins.
Risk
Similar to general.
Non-secretor and oligoscretor
What is it?
Non-secretor: almost no protein in the tests (1 to 2% of patients). Oligosecretor: very little protein.
How to follow up or manage
Standard treatment; followed by bone marrow and imaging tests.PETPositron emission tomography (PET) scan that shows the areas of the body with very active cells. Helps to see lesions in the bones and disease outside the bone marrow.MRI scan).
Risk
Similar to the general case, but it’s harder to see if the treatment is working.

Localized and aggressive forms

Solitary bone plasmacytoma
What is it?
A single tumor plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. in one bone, without myeloma in the rest of the marrow.
How to follow up or manage
RadiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. in the tumor area; then monitoring.
Risk
Approximately half progress to myeloma within 10 years.
Solitary extramedullary plasmacytoma
What is it?
A single tumor outside the bones, often in the nose, sinuses, or throat.
How to follow up or manage
RadiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. or surgery; then observation.
Risk
Progresses less than bone myeloma.
Extramedullary Disease
What is it?
Multiple myeloma with tumors in organs or soft tissues (skin, liver, lymph nodes, nervous system), in diagnosis or, more often, in relapses.
How to follow up or manage
Intensive treatment CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. e Specific biomarkersAntibodies with two “arms”: one grabs the T lymphocyte and the other the myeloma cell, joining them so that the lymphocyte destroys. Examples: teclistamab, elranatamab, talquetamab. are options in relapse; clinical trialsStudies comparing a new treatment with the best existing treatment may provide access to medications before approval. Participation is voluntary..
Risk
High risk.
Multiple myeloma
What is it?
5% or more plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. circulating in the blood. Primary (at the very beginning) or secondary (in a relapse).
How to follow up or manage
Intensive treatment and rapid response; transplant for those who can. clinical trialsStudies comparing a new treatment with the best existing treatment may provide access to medications before approval. Participation is voluntary..
Risk
Very high risk: the most aggressive form.

Related conditions (not myeloma)

AL Amyloidosis
What is it?
As fusion clampsThe smallest fragments of an antibody. There are two types, kappa and lambda. They are measured in the blood using the free light chain test; a significantly altered kappa/lambda ratio indicates a plasma cell clone. They fold badly and deposit themselves in the heart, kidneys, nerves, or liver.
How to follow up or manage
Treatment against the clone plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. (such as daratumumab with bortezomib, cyclophosphamide and dexamethasone) and care for the affected organs.
Risk
It mainly depends on the heart.
POEMS
What is it?
Rare syndrome with polyneuropathy, enlarged organs, hormonal changes. protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. It's almost always That's a good question.One of the two light chain types. Approximately 1 in every 3 multiple myeloma cases is lambda; it is also the most common type in AL amyloidosis.) and skin changes.
How to follow up or manage
RadiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. If the disease is localized to one area; otherwise, treatment as in myeloma and transplant.
Risk
Variable; nerves recover slowly.
MGRS (kidney-related)
What is it?
A small clone plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. That is not myeloma but damages the kidneys.
How to follow up or manage
Treatment targeting clones to protect the kidneys.
Risk
The risk is mainly for the kidneys.
Waldenström macroglobulinemia
What is it?
Lymphoma producing IgM. Not a myeloma.
How to follow up or manage
Self-treatment for lymphoma (e.g., BTK inhibitors or rituximab).
Risk
Generally progresses slowly.

And the risk for each person?

The risk doesn't just depend on the type. Doctors use the R-ISS or R2-ISS stage… beta-2 microglobulinProtein measured in the blood. High values indicate more disease and are included in the staging (ISS) calculation.The albumin, the LDHMeasured enzyme (lactate dehydrogenase). High values may indicate more active disease. and genetics) and are looking for high-risk changes: loss of 17pA fragment of chromosome 17 where the TP53 gene is located, which controls cell growth. If it is lost (17p deletion), the myeloma tends to be more aggressive. or mutation TP53Gene that acts as a brake on cells. When it is altered (mutated or lost), the myeloma responds worse to some treatments.It’s a condition where parts of your chromosomes swap places. t(4;14)Translocation: exchange of pieces between chromosomes 4 and 14. It doesn't count as high risk on its own; it does count when it's associated with gains in 1q or losses in 1p.t(14;16) or t(14;20) alongside gains 1qLong arm of chromosome 1. Having extra copies (a gain of 1q) is common and makes the disease more difficult to control, especially when combined with other changes. or a loss of 1 point, and very high beta-2 microglobulin with normal kidneys. Two or more changes = an even greater risk.

What is a plasmacytoma?

It's a tumor made of plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. patients, all together in one place. It’s the “physical” form of myeloma: a mass that is seen on imaging tests and that, sometimes, can be felt by touch.

Multiple myeloma: plasma cell disorder

In multiple myeloma, the plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. patients are spreading bone marrowThe soft tissue inside the bones where blood cells are made: red blood cells, white blood cells, platelets, and plasma cells. It is examined with a bone marrow tap (bone marrow scan) or biopsy. It affects many bones. In the plasma cell tumorA tumor formed by plasma cells in one location. It can be in a bone (osseous) or in soft tissue, such as the nose or throat (extramedullary).They come together as one.

Spread out or in one place

Solitary bone plasmacytoma

It originates within a bone, primarily in the vertebrae, pelvis, femur, or ribs. It can cause pain, fracture the bone, or compress the nerves of the spine.

The most common of the lonely ones

Extramedullary plasmacytoma

It originates outside the bones, in soft tissue: often in the nose, sinuses or throat, and more rarely in the stomach, intestines or lungs. It can cause a blocked nose, nosebleeds or hoarseness.

Out of the bone

Sometimes it is the first form of the disease.

In some patients, the plasma cell tumorA tumor formed by plasma cells in one location. It can be in a bone (osseous) or in soft tissue, such as the nose or throat (extramedullary). It's the first sign: it appears alone, before myeloma is present in the rest of the bone marrow. It's rare: in a large hospital, about 6 in every 100 patients with the disease plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. They had a solitary plasmacytoma.

First stage, in a few cases

How is it confirmed

A biopsy of the mass is performed to see if they are plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. from a single clone. Then myeloma is looked for in the rest of the body: bone marrow biopsyBone marrow examination, almost always in the pelvis, with local anaesthesia: a small amount of bone marrow is aspirated (bone marrow aspiration/myleogram) and a small piece of bone is taken (bone biopsy)., analyses of protein MMonoclonal protein: the antibody (or antibody fragment) that is identically produced by myeloma cells. It is measured in the blood and urine and is used to see if the treatment is working. and a whole-body imaging scanPETPositron emission tomography (PET) scan that shows the areas of the body with very active cells. Helps to see lesions in the bones and disease outside the bone marrow.- CT or MRI.

Full-body exams

Lonely, or with a little marrow

If there isn't plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. patients in the bone marrow, it's lonely. If there are a few, but less than 10%, it's called solitary with minimal bone marrow involvementWhen, in a solitary plasmacytoma, a few sick plasmocytes are found in the bone marrow, but less than 10%, the risk of progressing to myeloma is higher.And the risk of progressing to myeloma is quite a lot higher.

Change the risk

The treatment: radiotherapy

O plasma cell tumorA tumor formed by plasma cells in one location. It can be in a bone (osseous) or in soft tissue, such as the nose or throat (extramedullary). Solitary myeloma is generally treated with radiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. In the tumor area, every weekday for approximately 4 weeks. It often disappears. In the extramedularOutside the bone marrow: plasmacytoma tumors in organs or soft tissues (skin, liver, lymph nodes, nervous system). This indicates a more aggressive disease. You can also undergo surgery.

Around 4 weeks

The "children" of myeloma

In a patient who already has myeloma, new plasmacytomas can develop: attached to one bone, growing outside of it.bone marrowPlasma tumors that arise in a bone and grow outside of it into surrounding tissues carry a lower risk than free-floating tumors in organs.), or loose in other organsextramedullary diseaseMultiple myeloma with extramedullary deposits in organs or soft tissues, away from the bones (skin, liver, lymph nodes, nervous system). This indicates a more aggressive disease.They are like "sons" that the myeloma launches from the bone marrow.

In diagnosis or relapse

When it's a sign of a more aggressive illness

Loose plasmacytomas, away from the bones—on the skin, liver, lymph nodes, or nervous system—indicate a more aggressive myeloma. They are treated with the general myeloma treatment, often more intense, and sometimes with radiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain..

High risk

Watch closely for years.

Approximately half of solitary bone plasmacytomas and around three in ten extramedullary plasmacytomas progress to myeloma within 10 years. Therefore, regular monitoring and imaging tests are carried out, even if the tumor has disappeared.

Regular follow-up

Signs to immediately alert the team

A new pain in a bone, a lump that grows, weakness or tingling in the legs, or loss of control of urine or feces: contact your team or go to the emergency room immediately. There is hope, there is a way forward.

Don't wait for the appointment.
Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Simplified explanation for patients and families. Only the hematology team can say what type of multiple myeloma it is and what the best treatment is. Source: Caers et al., Journal of Hematology & Oncology 2018 — recomendações europeias para o plasmocitoma solitário ↗ · This does not replace the explanation from your medical team.

How does myeloma start?

It often starts without giving any signs. The first symptoms are vague and resemble those of more common illnesses, which is why the diagnosis can take months.

Fatigue and shortness of breath

A AnemiaLack of red blood cells or hemoglobin in the blood. Causes fatigue, paleness, and shortness of breath. � few red blood cells — causes fatigue that doesn't go away with rest, paleness and shortness of breath when climbing stairs. It’s one of the most frequent signs.

Very common

Bone pain

Back pain, rib pain, or pelvic pain that doesn't go away, that gets worse when you move, or that wakes you up at night. Sometimes a bone fractures with a small effort, or a vertebra “breaks down”.

Very common

Recurring infections

Pneumonia, urinary infections or areas that recur: myeloma takes the place of plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. Good, and there are not enough antibodies to defend the body.

Frequent appointments

Headquarters, prison of despair and confusion

When bones release calcium into the blood: excessive thirst, frequent urination, constipation, nausea, drowsiness or confusion. This is a situation that needs to be addressed quickly.

High calcium

Kidneys

The proteins in myeloma can damage the kidneys. Sometimes you may notice foamy urine or swollen legs; often it is only seen in tests. creatinineSubstance that the kidneys eliminate. When it rises in the blood, the kidneys are not working properly. admission

Often without symptoms

Other signs

Ant bites on the feet and hands, unexplained weight loss, black or bleeding spots on the nose.

Less frequent

Is there screening?

There is no screening for myeloma for the general population. It is often discovered incidentally, in a routine analysis with high total protein or high sedimentation rate, or when found during… MGUSMonoclonal gamopathy of undetermined significance. There is protein M (less than 3 g/dL) and less than 10% plasma cells in the bone marrow, without organ damage. It affects approximately 3 in 100 people over 50 years old, and most will never develop myeloma.Studies such as the iStopMMLarge study in Iceland that invited all the population over 40 to undergo tests to find MGUS and to see if screening helps.In Iceland, they are assessing whether it is worthwhile to track.

No general screening

Who is being monitored?

Who has MGUSMonoclonal gamopathy of undetermined significance. There is protein M (less than 3 g/dL) and less than 10% plasma cells in the bone marrow, without organ damage. It affects approximately 3 in 100 people over 50 years old, and most will never develop myeloma. Multiple myeloma latentSmoldering myeloma: protein M of 3 g/dL or higher, or 10% to 60% plasma cells in the bone marrow, but without organ damage. Approximately 10% per year evolve to active myeloma in the first 5 years. Get regular screenings, as they are the steps before myeloma. Having a close relative with myeloma slightly increases the risk, but on its own, there is no recommended screening: talk to your doctor.

Monitoring with analyses

The complete blood count

It's the blood test that counts the red blood cells and hemoglobin, the white blood cells and platelets. It's taken from the arm in just a few minutes. Shows the AnemiaLack of red blood cells or hemoglobin in the blood. Causes fatigue, paleness, and shortness of breath.But it’s not enough on its own to diagnose myeloma. It’s not a biopsy.

Blood test · minutes

The biochemistry

In the same harvest, one measures creatinineSubstance that the kidneys eliminate. When it rises in the blood, the kidneys are not working properly. (kidneys), the calcium, the albumin, the beta-2 microglobulinProtein measured in the blood. High values indicate more disease and are included in the staging (ISS) calculation. e a LDHMeasured enzyme (lactate dehydrogenase). High values may indicate more active disease.They show if there is damage and help to determine the stage of the disease.

Same crop

Looking for the protein M

A protein electrophoresisAnalysis that separates proteins from the blood (or urine). In myeloma, a narrow “peak” appears: protein M., a ImmunofixationBlood or urine analysis that precisely identifies which protein M is present: the type of heavy chain (G, A, D, E, or M) and light chain (kappa or lambda). And as free catenaryLoose pieces of antibody floating in the blood. The two types (kappa and lambda) are measured, as well as the ratio between them; a very high alteration indicates a clone of plasma cells., in the blood, and often 24-hour urine. These tests find and measure the myeloma.

Blood and urine

See the bones

Low-dose whole-body TAC, MRI or PETPositron emission tomography (PET) scan that shows the areas of the body with very active cells. Helps to see lesions in the bones and disease outside the bone marrow.-CT scans look for lesions in the bones. They see much more than old X-rays.

Imaging test

Bone marrow aspirate and bone marrow biopsy

Confirmation is made in the bone marrowThe soft tissue inside the bones where blood cells are made: red blood cells, white blood cells, platelets, and plasma cells. It is examined with a bone marrow tap (bone marrow scan) or biopsy.It's almost always in the sacrum, behind (sacral crestThe back and top of the hip bone, near the waist. This is the usual location for bone marrow aspiration and biopsy.). With local anaesthesia, a needle aspirates a small amount of bone marrow fluid.bone marrow scanProcedure in which a needle is used to draw a small amount of liquid bone marrow (almost always from the pelvis, with local anesthesia) to examine the cells under a microscope.) and take a small bone cylinder (bone marrow biopsyA small bone cylinder with marrow is removed, in the same procedure as the plasmacytoma. It shows the quantity of plasma cells and how they are arranged.).

Around 15 to 30 minutes

How are you feeling?

The anesthesia can feel a little burned at the beginning. When the marrow is aspirated, you will feel a pressure or a strong but short pain. Afterwards, you may feel sore for 1 or 2 days. You can ask for a sedative beforehand. You will go home on the same day.

In clinic

What you see in the bone marrow

The percentage of plasma cellsBlood cells that are born in the bone marrow and produce antibodies (immunoglobulins) to defend the body from infections. In multiple myeloma, an altered plasmacyte multiplies uncontrollably and all copies make the same antibody. and its appearance, and tests of the genetics of the myeloma cellsFISHBone marrow cell myeloma gene test, performed on the sample. Looks for chromosome changes that indicate whether the disease is high risk.) that show if it is high risk.

Results in 1 to 3 weeks

Talk to your doctor

If you have bone pain that doesn’t go away, fatigue and infections that keep recurring, ask your family doctor if it makes sense to request a protein electrophoresisAnalysis that separates proteins from the blood (or urine). In myeloma, a narrow “peak” appears: protein M.An early diagnosis protects the bones and kidneys. There is hope, there is a way.

Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

These symptoms may have many other causes, almost always simpler. They do not replace a consultation: if you recognize yourself here, speak to your doctor. Source: NHS — Multiple myeloma (sintomas e diagnóstico); critérios do IMWG (Rajkumar et al., Lancet Oncology 2014) ↗ · This does not replace the explanation from your medical team.

Asking for help is a right.

Treating myeloma isn't just about treating the disease; it's about treating the person. Being free from pain, sleeping well, and feeling emotionally well are all part of the treatment. Asking for help isn't weakness; it's a patient's right.

Being pain-free

Bone pain is common in myeloma, but don't suffer in silence. Tell the team how much it hurts, from 0 to 10. There are painkillers, radiotherapyTreatment with radiation directed to a specific area of the body. In myeloma, it is used in solitary plasmacytoma and to relieve bone pain. and other techniques that relieve.

Pain control = more strength for treatment

Pain Assessment

If the pain doesn't go away with your usual medication, ask to be seen. pain assessmentHospital appointment (pain unit) with doctors specialized in pain treatment who are not responding to usual medications. The referral is made by your doctor. pain unit of the hospital, or us palliative careTeams that treat pain and other symptoms and support the patient and family. They are not just for end-of-life care: they can help at any stage of the illness.which also help to control symptoms at any stage of the disease.

Ask your doctor

Sleep well

Poor sleep increases fatigue, pain, and sadness. Dexamethasone, pain, and worry disrupt sleep. Tell the team: often just changing the time of a medication or treating the pain is enough.

Sleeping is also treatment

Taking care of your mind

Fear, sadness, anxiety and emotional fatigue are normal for the patient and for those who care for them. Hospitals have psychologists and psych oncologySpecialized psychological support for people with cancer and their families, provided by psychologists and psychiatrists in hospitals.Book an appointment: talking helps you cope with the treatment.

Hospital psychologist

The social worker

All hospitals with hematology departments have social work services. A social workerSocial worker from the hospital who assists with support, transportation, paperwork, grants, accommodation, and patient and caregiver rights. assistance with transportation, medical prescriptions, Social Security benefits, and the disability certificateMulti-Disability Assessment Certificate: with 60% or more disability entitles you to tax benefits and other support. Obtained at the health center (social security office). (multi-purpose), the Informal Caregiver Status and accommodation.

Ask at your first appointment

Accommodation near the hospital

For those who live far away and need to be close to the hospital – for example, in the weeks following a transplant or a CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. � you may be eligible for housing support. The Casa Porto Seguro, from the APCL, in Lisbon, is one example; social workerSocial worker from the hospital who assists with support, transportation, paperwork, grants, accommodation, and patient and caregiver rights. Know what's happening in your area.

Speak early, before treatment

Money problems

Treatment within the public health system is free, but there are expenses: travel costs, time off work, medication, and the time of caregivers. If money is tight, let them know. social workerSocial worker from the hospital who assists with support, transportation, paperwork, grants, accommodation, and patient and caregiver rights.There are grants, exemptions, and assistance from associations.

Don't go through this alone.

Patient Rights Guides

The APCL's Patient Rights Manual and the Portuguese League Against Cancer's Oncology Patient Rights Guide explain, step by step, the support, grants, and how to apply for them. The links are below the video.

APCL and Portuguese League Against Cancer

Who can help already

SNS 24 (808 24 24 24): health questions at any time and psychological counseling. Line Cancro: 808 255 255. Associations: APLL in Porto, APCL in Lisbon and Coimbra, and the Portuguese League Against Cancer in all districts, from the mainland to the Azores and Madeira. Emergency: 112.

Keep these numbers.

You are not alone

Patient associations – APCL, APLL, Portuguese League Against Cancer – groups and other patients who have gone through the same are here to help. Ask for help early – before the pain, fatigue or bills become a burden. There is hope, there is a way.

Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Support and guidelines may change; always confirm with the hospital social worker and the APCL and Portuguese Cancer League guides. Source: Manual dos Direitos do Doente e Sobrevivente Hemato-Oncológico (APCL) e Direitos Gerais dos Doentes Oncológicos (LPCC) ↗ · This does not replace the explanation from your medical team.

The CAR-T journey

A treatment made from the patient's own cells, “taught” to recognise myeloma. See the steps, one by one.

1. The decision

The hematology team confirms if the patient meets all the criteria to... CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion..

First of all

2. Collection (apheresis)

A machine separates the white blood cells from the blood, where they are T lymphocytesWhite blood cells that attack cancerous cells. These are the ones that myeloma patients and specialists put to work attacking the myeloma, and these are used to manufacture CAR-T.The rest of the blood returns to the body.

About 4 to 6 hours, usually without a hospital stay

3. The frozen journey

The cells are frozen at about −196 °C in liquid nitrogen and sent to the factory.

Right after collection

4. Manufacturing

At the factory, they T lymphocytesWhite blood cells that attack cancerous cells. These are the ones that myeloma patients and specialists put to work attacking the myeloma, and these are used to manufacture CAR-T. They receive a new receptor (CAR) that recognizes the protein. BCMAThe protein found on the surface of myeloma cells (B cell maturation antigen). It is the target of CAR-T Carvykti and the bispecific teclistamab and elranatamab. of the myeloma cells. Then they are multiplied.

A few weeks

5. While waiting

If needed, bridging therapy keeps the myeloma under control until the cells arrive.

During manufacturing

6. Preparing the body

A short chemotherapy (lymphodepletion) “clears the way” for the cells CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. to grow

A few days before the infusion

7. The infusion

These cells CAR-TTreatment involving the patient’s own T lymphocytes, modified in the laboratory to recognize the myeloma and then reintroduced through infusion. The medication is administered to the patient via an intravenous infusion while they are hospitalized.

Day 0

8. The first two weeks

Daily monitoring: fever, low blood pressure, shortness of breath or confusion must be reported to the team straight away.

Days 1 to 14

9. Staying near the hospital

Regular check-ups continue for the next two weeks. The patient should stay near the hospital.

Up to about 4 weeks

10. From here on

Regular appointments and blood tests, scheduled by the doctor. There is hope, there is a way forward. Always talk to your haematology team.

Long-term follow-up
Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Approximate times: each hospital may organise treatment differently. Source: Folheto “Jornada do doente CAR-T”, Janssen-Cilag (Johnson & Johnson), ref. CP-507545, março de 2025 ↗ · This does not replace the explanation from your medical team.

Immunomodulatory drugs

Tablets such as lenalidomide, which slow the myeloma and help the body's defences.

At home

One tablet a day, at home, always at the same time. No hospital stay is needed.

Every day of the cycle

In cycles

Usually 21 days in a row of tablets and 7 days off: 28-day cycles.

28-day cycles

At the hospital

Blood tests and a haematology appointment to see whether the treatment is working and well tolerated.

Usually once per cycle

Precautions

A medicine to prevent blood clots may be needed. Fever, shortness of breath or pain in a leg: tell the team straight away.

Throughout treatment
Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Approximate times: each hospital may organise treatment differently. Source: EMA — Revlimid (lenalidomida) ↗ · This does not replace the explanation from your medical team.

Proteasome inhibitors

Medicines such as bortezomib, carfilzomib and ixazomib.

Bortezomib: an injection

At the day hospital, the nurse gives an injection under the skin of the belly or thigh.

A few minutes

How often

Once or twice a week, depending on the treatment schedule chosen by the doctor.

Weeks of treatment and weeks off

Carfilzomib: by drip

Carfilzomib is given into a vein, sitting in a chair at the day hospital, with fluids before and after.

About 30 minutes to 1 hour

Ixazomib: a tablet

Ixazomib is a tablet taken at home, once a week.

At home

Watch out

Tingling or pain in the feet and hands should be reported to the team: the dose can be adjusted.

Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Approximate times: each hospital may organise treatment differently. Source: EMA — Velcade (bortezomib) ↗ · This does not replace the explanation from your medical team.

Anti-CD38 antibodies

Daratumumab and isatuximab tag myeloma cells so that the immune system destroys them.

Daratumumab: injection in the belly

At the day hospital, the nurse slowly gives an injection under the skin of the belly.

About 3 to 5 minutes

First time: monitored

Before the injection, medicines are given to prevent reactions. The first time, you stay under observation for a while.

First dose: a few hours in hospital

How often

Usually weekly at first, then every 2 weeks and later once a month.

A schedule that gradually spaces out

Isatuximab: by drip

Isatuximab is given into a vein, in a chair at the day hospital.

A few hours
Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Approximate times: each hospital may organise treatment differently. Source: EMA — Darzalex (daratumumab) ↗ · This does not replace the explanation from your medical team.

Autologous transplant

Uses the patient's own stem cells to help the bone marrow recover after strong chemotherapy.

Preparing the collection

For a few days, injections are given that move the stem cells from the bone marrow into the blood.

A few days

The collection

A machine collects the stem cells from the blood. Then they are frozen.

A few hours, 1 or 2 days

The hospital stay

High-dose chemotherapy (melphalan) and, the next day or shortly after, the cells are given back through a vein.

A hospital stay of about 2 to 3 weeks

Recovery

While the bone marrow recovers, the risk of infection is higher. Nurses monitor you every day.

Until the defences come back

Back home

Frequent appointments and, often, treatment. MaintenanceMilder and longer treatment after induction and transplant, to keep the myeloma under control for a longer period. Often it is lenalidomide in tablet form. with tablets.

The following months
Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Approximate times: each hospital may organise treatment differently. Source: APCL — Mieloma múltiplo ↗ · This does not replace the explanation from your medical team.

Bispecific antibodies

“Ready-to-use” medicines that bring the T cell together with the myeloma cell.

Starting slowly

The first doses are smaller and gradually increase, so the body can adjust.

First week

In hospital at first

During the first doses the patient stays in hospital and is monitored for fever and other reactions.

A few days in hospital

Then: day hospital

An injection under the skin at the day hospital.

A few minutes, plus waiting time

How often

Every week and later, if the myeloma responds well, it may change to every 2 weeks.

For as long as it works

Preventing infections

The risk of infection is higher: vaccines, preventive medicines and sometimes immunoglobulin into a vein.

Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Approximate times: each hospital may organise treatment differently. Source: NICE — teclistamab (impacto nos serviços) ↗ · This does not replace the explanation from your medical team.

Belantamab

An antibody that carries a hidden medicine right inside the myeloma cell.

Before each dose

An eye appointment, because the medicine can affect the surface of the eye.

Before each dose

The treatment

A drip into a vein at the day hospital, together with other medicines (bortezomib or pomalidomide and dexamethasone).

About 30 minutes

How often

Usually every 3 weeks; the dose may be delayed if there are changes in the eyes.

Every 3 weeks

Eye care

Lubricating eye drops, and tell the team if your vision becomes blurred. Avoid driving if you cannot see well.

Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Approximate times: each hospital may organise treatment differently. Source: EMA — Blenrep (belantamab mafodotina) ↗ · This does not replace the explanation from your medical team.

High-risk smouldering myeloma

No symptoms, but a risk of progressing. There is now a treatment to delay that progression.

Daratumumab on its own

An injection under the skin of the belly, at the day hospital.

About 3 to 5 minutes

How often

Weekly at first; then the injections become less frequent.

Up to about 3 years

Monitoring

Regular tests and appointments to check that the disease is stable.

Hover over (or tap) the underlined words to see what they mean. The video will pause while you read.

Approximate times: each hospital may organise treatment differently. Source: IMF — aprovação europeia (AQUILA) ↗ · This does not replace the explanation from your medical team.

Multiple myeloma treatments

A simple explanation of the types of treatment available today and of what has changed year by year since 2025. Each piece of information has its source alongside. Your treatment plan is always decided with your haematology team.

How they work

Immunomodulatory drugs

Tablets that slow myeloma cells and activate the body's own defences. They are often the backbone of combinations and of maintenance after transplant.

Examples: lenalidomidapomalidomidatalidomida

When it is used: At almost every stage: first line, maintenance and relapse.

Trial numbers

Lenalidomide maintenance after initial treatment (DETERMINATION)

Median duration of maintenance — with transplant41,5 meses
Median duration of maintenance — without transplant36,4 meses
Source: ESMO OncologyPRO ↗
Source: EMA — Revlimid ↗ ▶ Watch the film

Proteasome inhibitors

They block the “shredder” the cell uses to get rid of old proteins. Myeloma cells make a lot of protein and end up dying from the excess.

Examples: bortezomibcarfilzomibixazomib

When it is used: First line (combinations such as VRd) and relapse.

Trial numbers

VRd (bortezomib + lenalidomide + dexamethasone) without immediate transplant: median progression-free time

VRd + maintenance (DETERMINATION)46,2 meses
VRd in patients without transplant (IMROZ control arm)54,3 meses
Source: ASCO Post / Cancer Letter ↗
Known side effects

D-VRd in CEPHEUS (with bortezomib and lenalidomide)

Infections91,9% (grave 40,1%)
Diarrhoea56,9%
Peripheral neuropathy (tingling, numbness)55,8%
Neutropenia55,8% (grave 44,2%)
Low platelets46,7% (grave 28,4%)

Neuropathy is mainly linked to bortezomib; giving bortezomib under the skin and once a week helps reduce it.

Source: CancerNetwork ↗

any grade severe (grade 3 or higher)

Source: EMA — Kyprolis ↗ ▶ Watch the film

Anti-CD38 antibodies

Antibodies that stick to a protein (CD38) on the surface of myeloma cells and tag them to be destroyed by the immune system.

Examples: daratumumabisatuximab

When it is used: Since 2025 in Europe, also as first-line treatment, in quadruplets with VRd. Still used at relapse and in high-risk smouldering myeloma.

Trial numbers

PERSEUS (with transplant): progression-free at 4 years

D-VRd (with daratumumab)84,3%
VRd67,7%
Source: ASCO Post ↗

IMROZ (without transplant): progression-free at 5 years

Isa-VRd (with isatuximab)63,2%
VRd45,2%
Source: ESMO ↗
Known side effects

Daratumumab: reactions during administration (COLUMBA)

In the belly, subcutaneous (3 to 5 minutes)13% (grave 2%)
Into a vein, intravenous (several hours)34% (grave 5%)
Source: OncLive / Haematologica ↗

PERSEUS: severe effects (grade 3 or 4), with and without daratumumab

Neutropenia — D-VRd62,1%
Neutropenia — VRd51%
Low platelets — D-VRd29,1%
Low platelets — VRd17,3%
Pneumonia — D-VRd10,5%
Pneumonia — VRd6,1%
Source: CancerNetwork ↗

any grade severe (grade 3 or higher)

Source: EMA — Darzalex ↗ ▶ Watch the film

Autologous transplant

The patient's own stem cells are collected, high-dose chemotherapy (melphalan) is given, and then the cells are returned so the bone marrow can recover.

Examples: melfalano em dose altaautotransplante

When it is used: Patients who are physically fit enough, usually after induction.

Trial numbers

DETERMINATION: median progression-free time

VRd + transplant67,5 meses
VRd without immediate transplant46,2 meses
Source: ASCO Post ↗

DETERMINATION: alive at 5 years (survival was similar)

With transplant80,7%
Without immediate transplant79,2%
Source: ASCO Post ↗
Source: APCL — Mieloma múltiplo ↗ ▶ Watch the film

CAR-T therapy

T cells are taken from the patient, modified in a laboratory to recognise the BCMA protein on myeloma cells, and given back in a single infusion.

Examples: cilta-cel (Carvykti)ide-cel (Abecma)

When it is used: In Europe, cilta-cel from the 2nd line (since 2024). Requires a certified hospital and close monitoring in the first weeks.

Trial numbers

CARTITUDE-4 (cilta-cel, from the 2nd line): median progression-free time

Cilta-cel (Carvykti)ainda não atingida
Standard treatment11,8 meses
Source: CancerNetwork, janeiro de 2026 ↗

CARTITUDE-4 (cilta-cel, from the 2nd line): patients after two and a half years

Progression-free — cilta-cel59,4%
Progression-free — standard treatment25,7%
Alive — cilta-cel76,4%
Alive — standard treatment63,8%
Source: CancerNetwork, janeiro de 2026 ↗

CARTITUDE-1 (cilta-cel, patients with many previous treatments): medians

Median progression-free time34,9 meses
Median survival60,7 meses
Source: CancerNetwork, junho de 2025 ↗

CARTITUDE-1: patients without progression and without any other treatment 5 years or more after a single infusion

Cilta-cel (Carvykti)33%
Source: Targeted Oncology, junho de 2025 ↗

Ide-cel (Abecma) versus standard treatments: average time without worsening

Ide-cel (Abecma)13,8 meses
Standard treatment4,4 meses
Source: EMA — Abecma ↗
Known side effects

Cilta-cel in CARTITUDE-4 (176 patients)

Cytokine release syndrome (fever, low blood pressure)76% (grave 1%)
Nervous system effects (all)21% (grave 3%)
ICANS (confusion, difficulty speaking)5% (grave 0%)
Other neurological effects17% (grave 2%)
Source: Legend Biotech, ASH ↗

CARTITUDE-4: severe effects, cilta-cel versus standard treatment

Severe infections — cilta-cel27%
Severe infections — standard25%
Severe drop in blood cells — cilta-cel94%
Severe drop in blood cells — standard86%
Source: Johnson & Johnson ↗

any grade severe (grade 3 or higher)

Source: EMA — Carvykti ↗
“CAR-T patient journey” leaflet (Johnson & Johnson) ↗ ▶ Watch the film

Bispecific antibodies

An antibody with “two arms”: one grabs the myeloma cell (BCMA or GPRC5D), the other grabs a T cell and brings them together so the T cell destroys it. They are “ready-to-use” medicines, with no individual manufacturing.

Examples: teclistamabelranatamabtalquetamablinvoseltamab

When it is used: Relapse. In 2026 the combination teclistamab + daratumumab was approved in Europe from the 2nd line.

Trial numbers

MajesTEC-3 (teclistamab + daratumumab): alive at 3 years

Teclistamab + daratumumab83,3%
Standard treatment65%
Source: FDA ↗

Patients who responded (already heavily treated)

Talquetamab (MonumenTAL-1)74%
Teclistamab alone (MajesTEC-1)63%
Source: PubMed — MonumenTAL-1 / NICE ↗
Known side effects

Teclistamab in MajesTEC-1 (165 patients)

Infections76,4% (grave 44,8%)
Cytokine release syndrome72,1% (grave 0,6%)
Neutropenia (low white blood cells)70,9% (grave 64,2%)
Anaemia52,1% (grave 37%)
ICANS (neurological effects)3% (grave 0%)
Source: New England Journal of Medicine (PMC) ↗

Talquetamab in MonumenTAL-1: effects specific to this medicine

Change in taste77%
Skin (dryness, peeling, itching)73%
Nails63%
Source: Healio, ASH 2023 ↗

any grade severe (grade 3 or higher)

Source: EMA — Tecvayli ↗ ▶ Watch the film

Antibody-drug conjugate (ADC)

An antibody that carries a toxic medicine “hidden” straight into the myeloma cell — which is why it is called a “Trojan horse”. It can affect the eyes, which means regular eye appointments.

Examples: belantamab mafodotina (Blenrep)

When it is used: Relapse, in combination (BVd or BPd). Approved in Europe in 2025.

Trial numbers

DREAMM-7 (BVd versus DVd)

Progression-free at 1 year — BVd71%
Progression-free at 1 year — standard51%
Alive at 3 years — BVd74%
Alive at 3 years — standard60%
Source: Ashtons / NICE ↗
Known side effects

Belantamab in DREAMM-7: eye effects

Eye effects — BVd (with belantamab)79%
Eye effects — DVd29%
Blurred vision — BVd66%
Severe corneal and vision changes — BVd77%

In most cases they improve when the dose is delayed or reduced. Regular eye appointments are needed.

Source: NEJM (DREAMM-7) / CancerNetwork ↗

any grade severe (grade 3 or higher)

Source: EMA — Blenrep ↗ ▶ Watch the film

CELMoDs (new generation of tablets)

More potent relatives of lenalidomide and pomalidomide, which break down proteins that myeloma cells depend on.

Examples: iberdomidamezigdomida

When it is used: Relapse. Iberdomide was approved in the USA in 2026; not yet in Europe.

Trial numbers

SUCCESSOR-2 (mezigdomide + Kd versus Kd): median progression-free time

MeziKd18 meses
Kd8,3 meses
Source: Indian Pharma Post, maio de 2026 ↗
Source: IMF — aprovação da iberdomida ↗

Smouldering myeloma

A phase without symptoms. Until recently it was only monitored. For high-risk cases there is now an approved treatment to delay progression.

Examples: daratumumab subcutâneo

When it is used: High-risk smouldering myeloma, approved in Europe in July 2025.

Trial numbers

AQUILA (high-risk smouldering myeloma), at 5 years

Progression-free — daratumumab63,1%
Progression-free — monitoring only40,8%
Alive — daratumumab93%
Alive — monitoring only87%
Source: AJMC / NEJM ↗
Source: IMF — aprovação europeia ↗ ▶ Watch the film

Side effects: percentage of trial patients who had each effect, at any grade (light bar) and severe, grade 3 or higher (dark part). Many are treated or prevented by the team; always talk to them if you notice any.

How to read the numbers: “median progression-free time” is the time after which half of the patients still did not have their disease getting worse; “not yet reached” means that, when the study was published, more than half of the patients were still progression-free. The numbers come from trials with selected patients and do not say what will happen to each person.

Abbreviations: V = bortezomib, R = lenalidomide, d = dexamethasone, K = carfilzomib, P = pomalidomide, D = daratumumab, Isa = isatuximab, B = belantamab.

News by year

2026

  1. 11 Nov 2026
    Portugal Isatuximab funded by the Portuguese NHS (SNS) in two combinations

    According to a Sanofi press release published by My Hematologia, the SNS now funds Isa-VRd (1st line, no transplant) and Isa-Kd (2nd line). To be confirmed in Infarmed's reports.

    Source: My Hematologia ↗
  2. 27 Oct 2026
    Trial Elranatamab alone beats three standard regimens (MagnetisMM-32)

    Phase 3 trial with 523 patients relapsing after anti-CD38 and lenalidomide: it met its main goal (progression-free time). More severe infections in the elranatamab arm.

    Source: IMF ↗
  3. 21 Aug 2026
    Approval Europe approves teclistamab + daratumumab from the 2nd line

    Based on the MajesTEC-3 trial. It is the first bispecific approved in Europe this early in treatment.

    Source: IMF ↗
  4. 13 Aug 2026
    Approval USA: first approval of a CELMoD (iberdomide)

    FDA accelerated approval for iberdomide + daratumumab + dexamethasone at relapse, based on minimal residual disease (EXCALIBER trial).

    Source: IMF ↗
  5. 11 Jun 2026
    Trial In vivo CAR-T KLN-1010: deep responses without conditioning chemotherapy

    Updated data from the phase 1 trial (ASCO and EHA 2026 congresses): evaluable patients had no detectable disease, with the CAR-T created inside the body from a single infusion.

    Source: Targeted Oncology ↗
  6. 2 Jun 2026
    Trial CEPHEUS: final analysis confirms daratumumab in the first line without transplant

    With more than 6 years of follow-up, adding daratumumab to VRd gave deeper and longer-lasting responses in patients who do not have a transplant.

    Source: Pharmacy Times ↗
  7. 30 May 2026
    Trial Mezigdomide halves the risk of progression (SUCCESSOR-2)

    Presented at the ASCO congress: median progression-free time of 18 months with MeziKd versus 8.3 months with Kd.

    Source: Targeted Oncology ↗
  8. 16 Apr 2026
    Approval England (NICE) recommends belantamab (Blenrep)

    About 1,600 people a year in England could receive BVd at relapse.

    Source: NICE ↗
  9. 25 Mar 2026
    Trial In vivo CAR-T ESO-T01 published in Nature Medicine

    First complete study of a CAR-T made inside the body in myeloma: the cancer was eliminated in 3 of 5 patients, but one patient died from a complication linked to a lesion outside the bone marrow.

    Source: Fierce Biotech ↗
  10. 5 Mar 2026
    Approval USA approves teclistamab + daratumumab (MajesTEC-3)

    The FDA approved the combination after at least one previous line; survival at 3 years was higher than with standard treatment.

    Source: FDA ↗
  11. 20 Jan 2026
    Trial iMMagine-1: anito-cel with 97% responses

    Phase 2 trial with 117 heavily treated patients: 97% responded and 68% had a complete response or better, with a single infusion.

    Source: Multiple Myeloma Hub ↗
  12. 7 Jan 2026
    Portugal São João announces the first CAR-T infusion in multiple myeloma

    ULS São João, recently certified for CAR-T therapies, announced the first infusion in a patient with multiple myeloma.

    Source: ULS São João ↗

2025

  1. 16 Dec 2025
    Portugal First CAR-T for myeloma at São João, through the SNS

    Gualter Macedo was the first multiple myeloma patient to receive CAR-T as standard treatment at São João Hospital.

    Source: Público ↗
  2. 10 Dec 2025
    Trial DREAMM-8: belantamab triples progression-free time

    With longer follow-up, median progression-free time was 32.6 months with BPd versus 12.5 months with PVd, in patients who had already had lenalidomide.

    Source: CancerNetwork ↗
  3. 9 Dec 2025
    Trial First patients treated with in vivo CAR-T KLN-1010

    At the ASH 2025 congress: the first 4 patients had no detectable disease after 1 month, with no cell collection, no factory and no conditioning chemotherapy.

    Source: OncLive ↗
  4. 6 Dec 2025
    Trial CARTITUDE-4: 80% progression-free at two and a half years in standard risk

    In patients with standard-risk cytogenetics treated with cilta-cel, 80.5% were progression-free and 87.3% alive at 30 months (ASH 2025 congress).

    Source: OncLive ↗
  5. 6 Nov 2025
    Approval USA approves daratumumab in high-risk smouldering myeloma

    Following the European approval in July, based on the AQUILA trial.

    Source: Multiple Myeloma Hub ↗
  6. 23 Oct 2025
    Approval USA approves belantamab (BVd) from the 3rd line

    Approval with warnings about eye toxicity, based on DREAMM-7.

    Source: FDA ↗
  7. 24 Jul 2025
    Approval Europe approves belantamab (Blenrep) in combination

    BVd and BPd at relapse, based on the DREAMM-7 and DREAMM-8 trials.

    Source: EMA ↗
  8. 23 Jul 2025
    Approval Europe approves the first treatment for smouldering myeloma

    Subcutaneous daratumumab alone for high-risk smouldering myeloma (AQUILA trial).

    Source: IMF ↗
  9. 23 Apr 2025
    Approval Europe approves linvoseltamab (Lynozyfic)

    New BCMA bispecific, conditional approval after at least 3 lines (LINKER-MM1 trial).

    Source: Myeloma Patients Europe ↗
  10. 7 Apr 2025
    Approval Europe approves D-VRd for all new diagnoses

    Daratumumab + VRd can now also be used in the 1st line in people who do not have a transplant (CEPHEUS trial).

    Source: IMF ↗
  11. 22 Jan 2025
    Approval Europe approves Isa-VRd in the 1st line without transplant

    Isatuximab + VRd for new diagnoses not having a transplant (IMROZ trial).

    Source: Myeloma Patients Europe ↗
  12. 12 Jan 2025
    Approval Joint European assessment of new cancer medicines begins

    New cancer medicines now have a common clinical assessment in the EU; price and reimbursement are still decided in each country.

    Source: EURORDIS ↗

A European or American approval does not mean the medicine is already available in the SNS: in Portugal, each medicine still goes through Infarmed's assessment.

What's coming — 2027, 2028, 2029

Dates expected by the sources themselves. They may change, and a positive trial result does not guarantee approval.

  1. 12 Dec 2026
    ASH 2026 Congress (New Orleans, 12–15 Dec.)

    The biggest haematology congress of the year, with new data on CAR-T, bispecifics and first line.

    Source: ASH ↗
  2. 23 Dec 2026
    US decides on anito-cel, a new CAR-T

    FDA target date for the accelerated approval of anitocabtagene autoleucel (iMMagine-1 trial).

    Source: Targeted Oncology ↗
  3. 2027
    Elranatamab in earlier lines goes for review

    With the MagnetisMM-5 and MagnetisMM-32 results, Pfizer announced it will submit the data to the agencies.

    Source: Fierce Pharma ↗
  4. 2027
    Mezigdomide: data submitted to health authorities

    After SUCCESSOR-2, an approval application is expected. There is no decision date yet.

    Source: IMF ↗
  5. 2027
    CAR-T as first-line treatment: results awaited

    The CARTITUDE-5 (no transplant) and CARTITUDE-6 (CAR-T instead of transplant) trials have not yet published results (October 2026). No official date.

    Source: J&J Medical Connect ↗
  6. 13 Jan 2028
    Joint European assessment extends to orphan medicines

    Many myeloma medicines are “orphan” drugs (rare disease). From this date they also go through the EU's common clinical assessment.

    Source: Cuatrecasas ↗
  7. 2029
    Many new cancer medicines arriving at the EMA

    An IQVIA estimate points to around 500 cancer products that may be assessed by the EMA between 2026 and 2029. In 2030 the joint assessment extends to all centrally authorised medicines.

    Source: ISPOR / IQVIA ↗
News from years ago…

How multiple myeloma was treated 1, 2, 5 and 10 years ago. It helps to see how much has changed in a short time.

1year2025

Four medicines right from the start

In 2025 Europe approved quadruplets in the first line: an anti-CD38 (daratumumab or isatuximab) together with bortezomib, lenalidomide and dexamethasone, also for people who do not have a transplant. At the end of the year, CAR-T arrived at São João as a standard treatment through the SNS.

How it was treated: New diagnosis: induction with a quadruplet, autologous transplant for eligible patients and lenalidomide maintenance. At relapse: bispecifics, CAR-T and belantamab.

Source: IMF — D-VRd ↗ Source: MPE — Isa-VRd ↗
2years2024

CAR-T arrives earlier

In March Europe extended ide-cel (Abecma) to patients with fewer previous treatments and, on 22 April, approved cilta-cel (Carvykti) from the 2nd line (CARTITUDE-4 trial). In the autumn, D-VRd was approved for patients having a transplant (PERSEUS trial).

How it was treated: CAR-T was no longer only the “last option”, but access in Portugal was still very limited.

Source: IMF — Abecma e Carvykti ↗ Source: Janssen — Carvykti 2.ª linha ↗
5years2021

The first CAR-T for myeloma

On 26 March the USA approved ide-cel (Abecma), the first CAR-T therapy for myeloma. Europe followed on 19 August, with conditional approval.

How it was treated: CAR-T was only possible after at least three lines (immunomodulator, proteasome inhibitor and anti-CD38). The backbone was still triplet + transplant + maintenance.

Source: FDA — ide-cel ↗ Source: BMS via Maestro — aprovação europeia ↗
10years2016

The first anti-CD38 antibody arrives

On 23 May Europe approved, under accelerated assessment, daratumumab — the first anti-CD38 antibody. At that time it could only be used alone, in patients who had already exhausted proteasome inhibitors and immunomodulators.

How it was treated: The standard treatment was a triple combination with bortezomib for induction, high-dose chemotherapy with an autologous transplant and then monitoring or maintenance. There was no CAR-T and no bispecifics. This was the setting in which Gualter was diagnosed, in 2015.

Source: Janssen — aprovação do daratumumab ↗